Investigational Device Exemption (IDE): Complete Guide

What Is an Investigational Device Exemption?

An IDE is a regulatory mechanism that exempts an investigational device from certain requirements of the FD&C Act (such as registration, listing, and premarket clearance) so that clinical studies can be conducted to gather data on the device's safety and effectiveness. The IDE program is governed by 21 CFR Part 812.

The IDE allows companies to ship investigational devices across state lines, import investigational devices, and conduct clinical trials involving human subjects — activities that would otherwise be prohibited for unapproved devices. IDE studies generate the clinical data typically needed for PMA applications and, in some cases, for 510(k) submissions.

Who Needs an IDE?

• Class III devices: New Class III devices almost always need IDE clinical data for PMA
• Novel Class II devices: When bench testing alone cannot demonstrate substantial equivalence
• Devices with new intended uses: Expanding the indication of a cleared device may require clinical data
• Breakthrough devices: Even with FDA's Breakthrough Device pathway, clinical evidence is typically needed

Significant Risk vs. Non-Significant Risk Devices

The regulatory requirements for IDE studies depend on whether the device is classified as significant risk (SR) or non-significant risk (NSR). This determination drives the level of FDA oversight:

An SR device is defined as one that is intended as an implant, is used in supporting or sustaining human life, is of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise presents a potential for serious risk to the health, safety, or welfare of a subject.

IDE Application Requirements

An IDE application for a significant risk device must be submitted to and approved by FDA before the clinical study begins. The application includes:

FDA Review Timeline

FDA has 30 days from receipt of the IDE application to approve, approve with conditions, or disapprove the application. If FDA does not act within 30 days, the IDE is considered approved by default. However, FDA frequently requests additional information, which restarts the 30-day clock.

Conducting a Clinical Investigation Under IDE

Once the IDE is approved, the sponsor must conduct the study in accordance with the approved investigational plan and FDA regulations. Key responsibilities include:

Sponsor Responsibilities

• Ensure investigators are qualified and conduct the study per protocol
• Monitor the investigation to ensure compliance and data quality
• Maintain accurate, complete, and current records
• Ship investigational devices only to qualified investigators
• Ensure proper labeling of investigational devices ("CAUTION — Investigational Device")

Investigator Responsibilities

• Conduct the investigation according to the signed investigator agreement and protocol
• Obtain and document informed consent from all subjects
• Report unanticipated adverse device effects (UADEs) to the sponsor, IRB, and FDA
• Maintain accurate case histories and device accountability records
• Retain records for two years after the investigation is completed or terminated

IDE Reporting and Record-Keeping

IDE holders have ongoing reporting obligations throughout the study and after completion:

• Unanticipated adverse device effects: Report to FDA, all reviewing IRBs, and all investigators within 10 working days
• Withdrawal of IRB approval: Notify FDA within 5 working days
• Progress reports: Submit to FDA and all reviewing IRBs at regular intervals (at least annually)
• Deviations from the investigational plan: Report significant protocol deviations to FDA
• Final report: Submit within 6 months of study completion or termination

Record Retention

All IDE records must be maintained for two years after the investigation is terminated or completed, or two years after the date the records are no longer required for supporting a premarket submission, whichever is later.

From IDE Study to Market Approval

IDE clinical data feeds directly into the marketing application. The pathway from IDE to market depends on the device classification:

• PMA pathway: Most SR IDE studies support PMA applications for Class III devices. The IDE clinical data becomes the primary evidence of safety and effectiveness.
• 510(k) pathway: Some IDE studies support 510(k) submissions when clinical data is needed to demonstrate substantial equivalence (less common).
• De Novo pathway: For novel devices without a predicate, IDE data may support a De Novo classification request with clinical evidence.

For PMA application details, see our PMA Guide. For 510(k) submission guidance, visit our 510(k) Guide.